Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4062 ARTÍCULOS , VIENDO DEL 1861 AL 1875

Sex differences in acupuncture effectiveness in animal models of Parkinson's disease: a systematic review

Lee SH, van den Noort M, Bosch P, Lim S.

BMC Complement Altern Med. 2016 Nov 3;16(1):430. doi: 10.1186/s12906-016-1405-5.

Clinically relevant cut-off values for the Parkinson's Disease Sleep Scale-2 (PDSS-2): a validation study

Muntean ML, Benes H, Sixel-Döring F, Chaudhuri KR, Suzuki K, Hirata K, Zimmermann J, Trenkwalder C.

Sleep Med. 2016 Aug;24:87-92. doi: 10.1016/j.sleep.2016.06.026. Epub 2016 Aug 24.

Association of LRRK2 R1628P variant with Parkinson's disease in Ethnic Han-Chinese and subgroup population

Zhang P, Wang Q, Jiao F, Yan J, Chen L, He F, Zhang Q, Tian B.

Sci Rep. 2016 Nov 4;6:35171. doi: 10.1038/srep35171.

Psychotropic Drug Development Strategies that Target Neuropsychiatric Etiologies in Alzheimer's and Parkinson's Diseases

Van der Schyf CJ.

Drug Dev Res. 2016 Dec;77(8):458-468. doi: 10.1002/ddr.21368. Epub 2016 Nov 4.

Risk and Prevention of Fracture in Patients With Major Medical Illnesses: A Mini-Review

Cummings SR, Eastell R.

J Bone Miner Res. 2016 Dec;31(12):2069-2072. doi: 10.1002/jbmr.3030.

Spanish version of the Parkinson's Disease Questionnaire-Carer (PDQ-Carer)

Ferrer-Cascales R, Cabañero-Martínez MJ, Sánchez-SanSegundo M, Congost-Maestre N, Jenkinson C.

Health Qual Life Outcomes. 2016 Nov 4;14(1):154. doi: 10.1186/s12955-016-0546-z.

"Manganese-induced neurotoxicity: a review of its behavioral consequences and neuroprotective strategies"

Peres TV, Schettinger MR, Chen P, Carvalho F, Avila DS, Bowman AB, Aschner M.

BMC Pharmacol Toxicol. 2016 Nov 4;17(1):57. doi: 10.1186/s40360-016-0099-0.

Parkinson Disease

Vaubel RA, Raghunathan A, Erickson LA.

Mayo Clin Proc. 2016 Nov;91(11):e155-e156. doi: 10.1016/j.mayocp.2016.06.017.

Ischemic stroke due to hypoperfusion in a patient with a previously unrecognized Danon disease

Marino M, Musumeci O, Paleologo G, Cucinotta M, Migliorato A, Rodolico C, Toscano A.

Neuromuscul Disord. 2016 Dec;26(12):890-894. doi: 10.1016/j.nmd.2016.09.025. Epub 2016 Oct 5.

Genetics of Parkinson's disease

Lill CM.

Mol Cell Probes. 2016 Dec;30(6):386-396. doi: 10.1016/j.mcp.2016.11.001. Epub 2016 Nov 4.

Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges

Kim D, Kim YS, Shin DW, Park CS, Kang JH.

J Clin Neurol. 2016 Oct;12(4):381-392. doi: 10.3988/jcn.2016.12.4.381.

Dysregulation of autophagy and mitochondrial function in Parkinson's disease

Wang B, Abraham N, Gao G, Yang Q.

Transl Neurodegener. 2016 Oct 31;5:19. doi: 10.1186/s40035-016-0065-1. eCollection 2016.

Biobehavioral Framework of Symptom and Health Outcomes of Uncertainty and Psychological Stress in Parkinson Disease

Austin KW, Ameringer SW, Starkweather AR, Cloud LJ, Sturgill JL, Elswick RK Jr.

J Neurosci Nurs. 2016 Dec;48(6):E2-E9. doi: 10.1097/JNN.0000000000000244.

Hydrogen therapy: from mechanism to cerebral diseases

Liu CL, Zhang K, Chen G.

Med Gas Res. 2016 Apr 4;6(1):48-54. doi: 10.4103/2045-9912.179346. eCollection 2016 Mar.

Noncoding RNA Regulation of Dopamine Signaling in Diseases of the Central Nervous System

Carrick WT, Burks B, Cairns MJ, Kocerha J.

Front Mol Biosci. 2016 Oct 25;3:69. doi: 10.3389/fmolb.2016.00069. eCollection 2016.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias